# Efficacy of Ferric Carboxymaltose (Ferinject®) in Anemic Patients Anticipating Pancreatoduodenectomy

> **NCT02628860** · PHASE2 · COMPLETED · sponsor: **National Cancer Center, Korea** · enrollment: 40 (actual)

## Conditions studied

- Pancreatic Cancer
- Anemia

## Interventions

- **DRUG:** Ferinject (Ferric Carboxymaltose)

## Key facts

- **NCT ID:** NCT02628860
- **Lead sponsor:** National Cancer Center, Korea
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2020-04-27
- **Final completion:** 2020-04-27
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2020-04-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02628860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02628860, "Efficacy of Ferric Carboxymaltose (Ferinject®) in Anemic Patients Anticipating Pancreatoduodenectomy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02628860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*